Management of Comorbidities in Kidney Disease in the 21st Century: Anemia, Bone Disease, Malnutrition, and Inflammation

Spis treści:
Dedication (Motrrell Michael Avram).
Introduction: Resumative synthesis of contents: It is time for further renoprotection (Morrell Michael Avram).
Hemoglobin predicts long–term survival in dialysis patients: A 15–year single–center longitudinal study and a correlation trend between prealbumin and hemoglobin (Morrell Michael Avram, Daniel Blaustein, Paul A. Fein, Naveen Goel, Jyotiprakas Chattopadhyay, and Neal Mittman).
Prospective trials on anemia of chronic disease: the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) (Madhumathi Rao and Brian J.G. Pereira).
Anemia of chronic Disease: Past, present, and future (Robert D. Toto).
Chronic kidney disease and cardiovascular disease in the Medicare population (Allan J. Collins, Shuling Li, David T. Gilbertson, Jiannong Liu, Shu–Cheng Chen, adn Charles A. Herzong).
Anemia as a risk factor for cardiovascular disease (Arema A. Pereira and Mark J. Sarnak).
Erythropoietin should be part of congestive heart failure management (Donald S. Silverberg, Dov Wexler, Miriam Blum, Doran Schwartz, Yoram Wollman, adn Adrian Iaina).
Effect of erythropoietin on exercise capacity in anemic patients with advanced heart failure (Donna M. Mancini and Chandra Kunavarapu).
Relationship of bioelectrical impedance parameters to nutrition and survival in peritoneal dialysis patients (Robert Mushnick, Paul A. Fein, Neal Mittman, Naveen Goel, Jyotiprakas Chattopadhyay, and Morrell M. Avram).
Treating azotemia–induced anemia with erythropoietin improves diabetic eye disease (Eli A. Friedman, Francis A. L′esperance, Jr., Clinton D. Brown, and David H. Berman).
Controversies in iron management (Allen R. Missenson and Chaim Charytan).
The safety and efficacy of an accelerated iron sucrose dosing regimen in patients with chronic kidney disease (Daniel A. Blaustein, Michael H. Schwenk, Jyoti Chattopadhyay, Harinder Singh, Rachid Daoui, Radjeep Gadh, and Morrell M. Avram).
Erythropoeitin dose variation in different facilities in different countries and its relationship to drug resistance (Roger N. Greenwood, Claudio Ronco, Fiorella Gastaldon, Alessandra Brendolan, Peter Homel, Len Usvyat, Lenore Bruno, Mary Carter, adn Nathan W. Levin).
Malnutrition and inflammation in peritoneal dialysis patients (Paul A. Fein, Neal Mittman, Rajdeep Gadh, Jyotiprakas Chattopadhyay, Daniel blaustein, Robert Mushnick ,a nd Morrell M. Avram).
Serum albumin concentration in dialysis patients: Why does it remain resistant to therapy (George A. Kaysen).
Transforming growth factor beta and progression of renal disease (Phyllis August and Manikkam Suthanthiran).
Obstructive nephropathy and renal fibrosis: the role of bone morphogenic protein–7 and hepatocyte growth factor (Saulo Klahr and Jeremiah Morrissey).
Overview of renal bone disease: Causes of treatment failure, clinical observations, the changing pattern of bone lesions, and future therapeutic approach (Francisco lloach and Elvira Fernandez).
New assays for parathyroid hormone (PTH) and the relevance of PTH fragments in renal failure (William G. Goodman).
An update on vitamin D as related to nephrology practice: 2003 (Jack W. Coburn).
The impact of calcimimetics on mineral metabolism and secondary hyperparathyroidism in end–stage renal disease (Geoffrey A. Block)